To explore the effects of the bilateral fallopian tube resection during the hysterectomy of patients on their ovarian function and serum tumor markers levels. Methods: The clinical data of 120 patients who had undergone total hysterectomy from January 2020 to December 2022 were collected retrospectively. These patients were divided into 55 cases with bilateral fallopian tube resection in group A and 65 cases with the reserved bilateral fallopian tube in group B according to the bilateral tubal resection during the hysterectomy or not. The surgical indictors, the preoperative and postoperative indicators related to ovarian function, such as luteinizing hormone(LH), estradiol(E2), follicle-stimulating hormone(FSH), anti-Muller's tube hormone(AMH) and antral follicle count(AFC), and the level of oncology indicators, such as the serum cancer antigen(CA) 125, CA199, and vascular endothelial growth factors-C(VEGF-C), of the patients were compared between the two groups. Results: There was no significant difference in the surgical indicators of the patients between the two groups(P>0.05). The incidence of the pelvic encapsulated effusion of the patients in group A was significantly lower than that of the patients in group B(P<0.05). In 3 months after operation, the levels of LH and FSH of the patients in the two groups had increased significantly, and the levels of E2, AMH and AFC of the patients in the two groups had decreased significantly, and the level of E2 of the patients in group A was significantly lower than that of the patients in group B(P<0.05). The serum levels of CA125, CA199 and VEGF-C of the patients in the two groups in 3 months after operation had decreased significantly, and which(16.20±4.36 IU/ml, 10.60±3.12 IU/ml and 165.14±30.24 pg/ml) of the patients in group A were significantly lower than those(25.83±6.12 IU/ml, 16.02±4.13 IU/ml and 200.25±32.38 pg/ml) of the patients in group B(all P<0.05). Conclusion: The bilateral fallopian tube resection during hysterectomy of the patients does not aggravate their ovarian hypofunction, and which is of the greater oncology value.